Acute respiratory distress syndrome due to COVID-19. Clinical and prognostic features from a medical Critical Care Unit in Valencia, Spain.
Aged
Antibodies, Monoclonal, Humanized
/ therapeutic use
COVID-19
/ complications
Comorbidity
Critical Illness
Cross Infection
/ epidemiology
Diabetes Mellitus
/ epidemiology
Dyslipidemias
/ epidemiology
Female
Humans
Hypertension
/ epidemiology
Length of Stay
Male
Middle Aged
Prognosis
Prone Position
Respiration, Artificial
/ methods
Respiratory Distress Syndrome
/ etiology
Retrospective Studies
SARS-CoV-2
Spain
/ epidemiology
Steroids
/ therapeutic use
Tracheostomy
/ statistics & numerical data
ARDS
COVID-19
Critical care
Cuidados críticos
Neumonía viral
SARS-CoV-2
SDRA
Viral pneumonia
Journal
Medicina intensiva
ISSN: 2173-5727
Titre abrégé: Med Intensiva (Engl Ed)
Pays: Spain
ID NLM: 101717568
Informations de publication
Date de publication:
Historique:
received:
07
05
2020
revised:
08
06
2020
accepted:
12
06
2020
pubmed:
14
9
2020
medline:
14
1
2021
entrez:
13
9
2020
Statut:
ppublish
Résumé
Information from critically ill coronavirus disease 2019 (COVID-19) patients is limited and in many cases coming from health systems approaches different from the national public systems existing in most countries in Europe. Besides, patient follow-up remains incomplete in many publications. Our aim is to characterize acute respiratory distress syndrome (ARDS) patients admitted to a medical critical care unit (MCCU) in a referral hospital in Spain. Retrospective case series of consecutive ARDS COVID-19 patients admitted and treated in our MCCU. 36-bed MCCU in referral tertiary hospital. SARS-CoV-2 infection confirmed by real-time reverse transcriptase-polymerase chain reaction (RT-PCR) assay of nasal/pharyngeal swabs. None MAIN VARIABLES OF INTEREST: Demographic and clinical data were collected, including data on clinical management, respiratory failure, and patient mortality. Forty-four ARDS COVID-19 patients were included in the study. Median age was 61.50 (53.25 - 67) years and most of the patients were male (72.7%). Hypertension and dyslipidemia were the most frequent co-morbidities (52.3 and 36.4% respectively). Steroids (1mg/Kg/day) and tocilizumab were administered in almost all patients (95.5%). 77.3% of the patients needed invasive mechanical ventilation for a median of 16 days [11-28]. Prone position ventilation was performed in 33 patients (97%) for a median of 3 sessions [2-5] per patient. Nosocomial infection was diagnosed in 13 patients (29.5%). Tracheostomy was performed in ten patients (29.4%). At study closing all patients had been discharged from the CCU and only two (4.5%) remained in hospital ward. MCCU length of stay was 18 days [10-27]. Mortality at study closing was 20.5% (n 9); 26.5% among ventilated patients. The seven-week period in which our MCCU was exclusively dedicated to COVID-19 patients has been challenging. Despite the severity of the patients and the high need for invasive mechanical ventilation, mortality was 20.5%.
Identifiants
pubmed: 32919796
pii: S0210-5691(20)30245-X
doi: 10.1016/j.medin.2020.06.015
pmc: PMC7833115
pii:
doi:
Substances chimiques
Antibodies, Monoclonal, Humanized
0
Steroids
0
tocilizumab
I031V2H011
Types de publication
Journal Article
Observational Study
Langues
eng
spa
Sous-ensembles de citation
IM
Pagination
27-34Informations de copyright
Copyright © 2020 Elsevier España, S.L.U. y SEMICYUC. All rights reserved.
Références
Crit Care Med. 2013 Mar;41(3):725-31
pubmed: 23318488
Am J Respir Crit Care Med. 2012 Jul 1;186(1):56-64
pubmed: 22517788
N Engl J Med. 2013 Jun 6;368(23):2159-68
pubmed: 23688302
Intensive Care Med. 2020 May;46(5):854-887
pubmed: 32222812
JAMA. 2020 Apr 28;323(16):1574-1581
pubmed: 32250385
JAMA. 2020 Mar 17;323(11):1061-1069
pubmed: 32031570
Clin Infect Dis. 2007 Mar 1;44 Suppl 2:S27-72
pubmed: 17278083
JAMA. 2020 May 26;323(20):2052-2059
pubmed: 32320003
Med Intensiva (Engl Ed). 2020 Dec;44(9):589-590
pubmed: 32425288
Med Intensiva (Engl Ed). 2020 Aug - Sep;44(6):371-388
pubmed: 32360034
Am J Respir Crit Care Med. 2007 May 1;175(9):935-42
pubmed: 17234903
BMJ. 2020 Mar 26;368:m1091
pubmed: 32217556
Lancet. 2020 Feb 15;395(10223):497-506
pubmed: 31986264
JAMA Intern Med. 2020 Jul 1;180(7):934-943
pubmed: 32167524
N Engl J Med. 2020 May 21;382(21):2012-2022
pubmed: 32227758
Shock. 2017 May;47(5):588-592
pubmed: 27861258
N Engl J Med. 2020 Jul 16;383(3):e12
pubmed: 32343505
Am J Infect Control. 2008 Jun;36(5):309-32
pubmed: 18538699
Am J Respir Crit Care Med. 2017 May 1;195(9):1253-1263
pubmed: 28459336
JAMA. 2020 Jun 9;323(22):2329-2330
pubmed: 32329799
Ann Am Thorac Soc. 2020 Jul;17(7):839-846
pubmed: 32255382
Lancet Respir Med. 2020 May;8(5):475-481
pubmed: 32105632
Shock. 2016 Sep;46(3):254-60
pubmed: 27172160
Clin Infect Dis. 2016 Mar 15;62(6):755-60
pubmed: 26679623
Crit Care Med. 2009 Aug;37(8):2350-8
pubmed: 19531944
Med Intensiva (Engl Ed). 2018 Jun - Jul;42(5):266-273
pubmed: 28882325